Youxiang Chen

机构：Nanchang University, First Affiliated Hospital of Jiangxi Medical College, First Affiliated Hospital of Nanchang University, Xi'an Jiaotong University · ORCID：0000-0003-4218-6133

发表论文 95 篇 · 总被引 877 次 · h-index 13

代表论文

• Risankizumab for Ulcerative Colitis (2024 · JAMA · 被引 120)
• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 107)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 95)
• Thalidomide mitigates Crohn's disease colitis by modulating gut microbiota, metabolites, and regulatory T cell immunity (2024 · Journal of Pharmaceutical Analysis · 被引 7)
• Risk factors and a nomogram for prediction of post-endoscopic submucosal dissection electrocoagulation syndrome for superficial colorectal lesions (2024 · Surgical Endoscopy · 被引 6)
• Radiomics analysis based on CT for predicting lymph node metastasis and prognosis in duodenal papillary carcinoma (2024 · Insights into Imaging · 被引 5)